GLP-1 Vision Loss Warning: What the FDA Actually Found
Every GLP-1 drug label must now warn about NAION, a rare optic nerve stroke that can take vision in one eye. The viral numbers are accurate. Here is what sits around them.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
What the FDA Reviewed, in Four Parts
Non-arteritic anterior ischemic optic neuropathy is caused by reduced blood flow to the front of the optic nerve (the optic disc). It typically shows up as sudden, painless vision loss in one eye, often noticed on waking, and the loss can be permanent. The FDA notes the underlying cause is not completely understood. Risk factors include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease (FDA Drug Safety Communication, November 9, 2026).
The FDA pooled 126 randomized trials: 78,217 patients on a GLP-1 drug (156,947 person-years) and 56,036 on placebo or a non-GLP-1 glucose-lowering drug (131,932 person-years). It found 15 probable NAION events: 10 on GLP-1 drugs and 5 on placebo, giving 6.4 versus 3.8 per 100,000 person-years. That is a gap of about 2.6 cases per 100,000 person-years, built on very few events.
In the FDA Sentinel cohort of adults with type 2 diabetes starting treatment between 2019 and 2024, NAION rates were 30 to 32 per 100,000 person-years on GLP-1 drugs, 31 on SGLT-2 inhibitors and 26 on DPP-4 inhibitors. The difference against SGLT-2 inhibitors was not significant (HR 1.19, 95% CI 0.91 to 1.54); against DPP-4 inhibitors it was (HR 1.43, 95% CI 1.02 to 2.01).
The FDA review of animal data did not identify a way GLP-1 drugs could raise NAION risk. Its adverse event reports were hard to read because NAION risk factors overlap with conditions common in people taking these drugs. The agency still concluded there is a potential increased risk and noted NAION cases have been reported for every marketed GLP-1 product.
What the Data Shows
What Do the Major NAION Studies Show?
The studies split. Registry and single-center studies in people with diabetes tend to find a raised relative risk. The largest multi-database study (OHDSI, 37.1 million people) found a modest increase, smaller than earlier reports, not a null result. The randomized-trial meta-analyses disagree: one of 78 semaglutide trials found significantly higher odds of NAION (OR 3.92, 95% CI 1.02 to 15.02), while one of 20 GLP-1 trials did not (OR 1.50, 95% CI 0.49 to 4.63). Both rest on few cases because NAION is rare, so their intervals are wide.
| Study | Population | NAION finding |
|---|---|---|
| FDA pooled analysis of 126 RCTs | 134,253 patients across GLP-1 RA development programs | 10 probable NAION events on GLP-1 RAs vs 5 on comparator: 6.4 vs 3.8 per 100,000 person-years |
| FDA Sentinel cohort (type 2 diabetes) | New users, 2019 to 2024, FDA Sentinel commercial network | GLP-1 RA vs SGLT-2 inhibitor HR 1.19 (95% CI 0.91 to 1.54, not significant); vs DPP-4 inhibitor HR 1.43 (1.02 to 2.01) |
| Hathaway 2024, JAMA Ophthalmol | One academic neuro-ophthalmology center: 710 patients with diabetes, 979 with overweight or obesity | Semaglutide HR 4.28 in type 2 diabetes and 7.64 in overweight or obesity |
| Simonsen 2025, Diabetes Obes Metab | Danish and Norwegian registries, type 2 diabetes, vs SGLT-2 inhibitors | Pooled HR 2.81; 1.41 extra cases per 10,000 person-years |
| Chou 2025, Ophthalmology | Records from 160 health care organizations in 21 countries | No significant association in diabetes-only, obesity-only or combined groups |
| Cai 2025, JAMA Ophthalmol (OHDSI) | 14 databases, 37.1 million people with type 2 diabetes | Modest increase: HR 2.27 (95% CI 1.16 to 4.46) vs empagliflozin on the specific NAION definition; within-person IRR 1.32 (1.14 to 1.54). Not significant vs empagliflozin, sitagliptin or glipizide on the broader sensitive definition |
| Li 2026, Diabetes Care | Meta-analysis of 20 RCTs, 83,288 participants | Ischemic optic neuropathy OR 1.50 (95% CI 0.49 to 4.63, not significant) |
| Natividade 2025, JAMA Ophthalmol | Meta-analysis of 78 semaglutide RCTs, 73,640 participants | NAION OR 3.92 (95% CI 1.02 to 15.02, significant); authors say evidence is still insufficient for definitive conclusions |
Key Takeaways
- Since November 9, 2026 the FDA requires NAION information in the Warnings and Precautions section of every GLP-1 drug label, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo.
- In the FDA pooled analysis of 126 trials there were 10 probable NAION cases on GLP-1 drugs and 5 on placebo: 6.4 versus 3.8 per 100,000 person-years.
- National registry studies in type 2 diabetes found a higher relative risk with semaglutide: HR 2.19 in Denmark and a pooled HR 2.81 against SGLT-2 inhibitors in Denmark and Norway.
- The absolute risk is small. A 2026 meta-analysis put NAION at 0.09% of GLP-1 users, a number needed to harm of about 2,700.
- Warning signs per the FDA: sudden painless vision loss in one eye (often on waking), blind spots or tunnel vision, distorted colors, and blurry or hazy central vision.
- Someone who has had NAION in one eye has a higher risk in the other eye and a higher risk of recurrence.
- Whether GLP-1 drugs cause NAION. The FDA called the risk potential and its animal data review found no mechanism.
- How precise the trial estimate is. It rests on 15 events, and the trial meta-analyses disagree: 20 GLP-1 RCTs found no significant link (OR 1.50, 95% CI 0.49 to 4.63), while 78 semaglutide RCTs did (OR 3.92, 95% CI 1.02 to 15.02).
- Whether the risk is the same for weight-loss users without diabetes. The FDA Sentinel study only covered type 2 diabetes, and obesity-only results conflict between studies.
- Whether risk differs between semaglutide, tirzepatide and older GLP-1 drugs. Most published studies focus on semaglutide.
- Whether dose or treatment length matters. In the Danish cohort the median time from first prescription to NAION was 22.2 months, but no study cited here shows a dose-response.
Frequently Asked Questions
Did the FDA say GLP-1 drugs cause blindness?
No. The FDA said there is a potential increased risk of NAION, a rare condition that causes sudden, painless vision loss in one eye that can be permanent. It did not establish that the drugs cause it, and its review of animal data did not find a mechanism. It is requiring the risk to be listed in the Warnings and Precautions section of every GLP-1 label.
How common is NAION on Ozempic, Wegovy, Mounjaro or Zepbound?
Rare. In the FDA pooled analysis of 126 trials, NAION occurred at 6.4 cases per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or comparator, based on 10 and 5 cases. In real-world adults with type 2 diabetes, FDA Sentinel data showed 30 to 32 cases per 100,000 person-years on GLP-1 drugs versus 31 on SGLT-2 inhibitors and 26 on DPP-4 inhibitors.
What are the warning signs of NAION?
The FDA lists sudden, painless vision loss in one eye that may be noticed on waking; blurred or missing parts of vision such as blind spots or tunnel vision; distorted colors; and reduced central sharpness, like blurry or hazy spots. It advises contacting a health care professional right away if any of these appear.
Should I stop my GLP-1 because of the NAION warning?
The FDA advice is narrower than that. It tells patients to know the symptoms and seek care right away if they occur. Anyone who has had a NAION event should talk with their prescriber about whether to continue, and clinicians are told to consider stopping the drug after NAION unless the benefits clearly outweigh the risk. The North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology recommend shared decision-making between patient and care team.
Does the warning apply to tirzepatide and pills like Rybelsus?
Yes. The FDA list covers every approved GLP-1 receptor agonist, including tirzepatide (Mounjaro, Zepbound), oral semaglutide (Rybelsus), orforglipron (Foundayo), liraglutide, dulaglutide, exenatide and lixisenatide combinations. A 2025 JAMA Network Open study of semaglutide or tirzepatide in type 2 diabetes found NAION in 0.04% of users versus 0.02% of matched controls over two years (HR 1.76).
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
GLP-1 receptor agonists are prescription drugs. Talk to your prescriber before starting, stopping or changing one. The FDA advises contacting a health care professional right away about sudden vision changes.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.